TrialThe oncologist2025

Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER).

Carmine De Angelis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.